Business Description
Vertex Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92532F1003
Share Class Description:
LTS:0QZU: Ordinary SharesCompare
Compare
Traded in other countries / regions
VRTX.USA0QZU.UKVRTX.MexicoVRTX34.BrazilVX1.GermanyVRTX.Austria1VRTX.Italy IPO Date
2014-11-10Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.83 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.11 | |||||
| Debt-to-EBITDA | 3.29 | |||||
| Interest Coverage | 110.38 | |||||
| Altman Z-Score | 12.33 | |||||
| Beneish M-Score | -1.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.2 | |||||
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 13.9 | |||||
| 3-Year FCF Growth Rate | 3.5 | |||||
| 3-Year Book Growth Rate | 26.8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 9.54 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.48 | |||||
| 9-Day RSI | 49.95 | |||||
| 14-Day RSI | 48.32 | |||||
| 6-1 Month Momentum % | 6.66 | |||||
| 12-1 Month Momentum % | 33.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.47 | |||||
| Quick Ratio | 2.2 | |||||
| Cash Ratio | 1.64 | |||||
| Days Inventory | 209.58 | |||||
| Days Sales Outstanding | 57.04 | |||||
| Days Payable | 89.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 0.89 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.12 | |||||
| Operating Margin % | 39.89 | |||||
| Net Margin % | -4.52 | |||||
| FCF Margin % | -12.72 | |||||
| ROE % | -2.89 | |||||
| ROA % | -2.17 | |||||
| ROIC % | -75.33 | |||||
| ROC (Joel Greenblatt) % | 17.21 | |||||
| ROCE % | 1.61 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 24.13 | |||||
| PE Ratio without NRI | 917.9 | |||||
| Shiller PE Ratio | 81.14 | |||||
| PEG Ratio | 22.17 | |||||
| PS Ratio | 11.47 | |||||
| PB Ratio | 7.72 | |||||
| Price-to-Tangible-Book | 8.8 | |||||
| EV-to-EBIT | 388.37 | |||||
| EV-to-Forward-EBIT | 20.74 | |||||
| EV-to-EBITDA | 223.56 | |||||
| EV-to-Forward-EBITDA | 20.91 | |||||
| EV-to-Revenue | 10.89 | |||||
| EV-to-Forward-Revenue | 9.68 | |||||
| EV-to-FCF | -85.63 | |||||
| Price-to-Projected-FCF | 2.77 | |||||
| Price-to-Median-PS-Value | 0.84 | |||||
| Price-to-Graham-Number | 18.94 | |||||
| Price-to-Net-Current-Asset-Value | 37.76 | |||||
| Earnings Yield (Greenblatt) % | 0.26 | |||||
| FCF Yield % | -1.12 | |||||
| Forward Rate of Return (Yacktman) % | 2.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Vertex Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 10,625.8 | ||
| EPS (TTM) ($) | -1.99 | ||
| Beta | 0.55 | ||
| Volatility % | 24.43 | ||
| 14-Day RSI | 48.32 | ||
| 14-Day ATR ($) | 10.52738 | ||
| 20-Day SMA ($) | 476.332091 | ||
| 12-1 Month Momentum % | 33.86 | ||
| 52-Week Range ($) | 347.54 - 519.66 | ||
| Shares Outstanding (Mil) | 257.53 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Vertex Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Vertex Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Vertex Pharmaceuticals Inc Frequently Asked Questions
What is Vertex Pharmaceuticals Inc(LTS:0QZU)'s stock price today?
The current price of LTS:0QZU is $468.63. The 52 week high of LTS:0QZU is $519.66 and 52 week low is $347.54.
When is next earnings date of Vertex Pharmaceuticals Inc(LTS:0QZU)?
The next earnings date of Vertex Pharmaceuticals Inc(LTS:0QZU) is 2025-02-05 Est..
Does Vertex Pharmaceuticals Inc(LTS:0QZU) pay dividends? If so, how much?
Vertex Pharmaceuticals Inc(LTS:0QZU) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers